AB Active ETFs Inc - AB Corporate Bond ETF
EYEG
Get informed when a big investor buys or sells
+ FollowMarket Cap$208.51M
Close$
$2.03
94% downside
Current Fair Value
94% downsideOvervalued by 94% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $208.51 Million |
|---|---|
| Enterprise Value | $203.02 Million |
| Dividend Yield | $1.71 (5.07%) |
| Earnings per Share | $-2.64 |
| Beta | 0.21 |
| Outstanding Shares | 6,177,679 |
Return
| Return on Equity | -65.18% |
|---|---|
| Return on Assets | -46.21% |
| Return on Invested Capital | 22.08% |
Valuation & Multiples
| P/E Ratio | -13.5 |
|---|---|
| PEG | 395.65 |
| Price to Sales | - |
| Price to Book Ratio | 16.88 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 42.95 |
| Enterprise Value to Net Income | -19 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.09 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 8, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Eyegate Pharmaceuticals Inc
CEO: Stephen From BUFM actively manages FLEX options in efforts to participate in the price return of the SPDR S&P 500 ETF (SPY), up to a cap, and provide partial downside protection over an outcome period that ranges from 90 to 120 days. In exchange for ...